Bio-Rad Laboratories Inc (BIO)

705.99
+3.20(+0.46%)
  • Volume:
    50,758
  • Bid/Ask:
    706.69/707.71
  • Day's Range:
    705.99 - 710.09

BIO Overview

Prev. Close
702.79
Day's Range
705.99-710.09
Revenue
2.7B
Open
701.29
52 wk Range
472.84-710.79
EPS
135.93
Volume
50,758
Market Cap
21.12B
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
127,265
P/E Ratio
5.17
Beta
0.84
1-Year Change
32.48%
Shares Outstanding
29,763,614
Next Earnings Date
Jul 29, 2021
What is your sentiment on Bio-Rad Laboratories Inc?
or
Vote to see community's results!

Bio-Rad Laboratories Inc News

Bio-Rad Laboratories Inc Analysis

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesNeutralNeutralBuyStrong BuyStrong Buy
Technical IndicatorsStrong SellStrong SellStrong BuyStrong BuyStrong Buy
SummarySellSellStrong BuyStrong BuyStrong Buy

Bio-Rad Laboratories Inc Company Profile

Bio-Rad Laboratories Inc Company Profile

Bio-Rad Laboratories, Inc. develops, manufactures, and markets life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. The company offers products and systems to separate complex chemical and biological materials, as well as to identify, analyze, and purify components. It operates in two segments, Life Science and Clinical Diagnostics. The Life Science segment develops, manufactures, and markets a range of reagents, apparatus, and laboratory instruments that are used in research techniques, biopharmaceutical production processes, and food testing regimes. It focuses on selected segments of the life sciences market in proteomics, genomics, biopharmaceutical production, cell biology, and food safety. This segment serves universities and medical schools, industrial research organizations, government agencies, pharmaceutical manufacturers, biotechnology researchers, food producers, and food testing laboratories. The Clinical Diagnostics segment designs, manufactures, sells, and supports test systems, informatics systems, test kits, and specialized quality controls for clinical laboratories in the diagnostics market. This segment offers reagents, instruments, and software, which address specific niches within the in vitro diagnostics test market. It sells its products to reference laboratories, hospital laboratories, state newborn screening facilities, physicians’ office laboratories, transfusion laboratories, and insurance and forensic testing laboratories. The company offers its products through its direct sales force, as well as through distributors, agents, brokers, and resellers. Bio-Rad Laboratories, Inc. was founded in 1952 and is headquartered in Hercules, California.

Read More
  • Sold before the crazy beat..
    0
    • Massively undervalued!
      0
      • RDGL 0.125 By 1/16/2021 FDA will provide a final decision to grant or deny their request for breakthrough designation.
        0
        • Incredible earnings! Come on in now
          0
          • To the moon!!!!!
            0
            • ATTENTION! READ HERE "As of August 2020, Bio-Rad had 37% ownership of Sartorius, and shares of Sartorius have increased about a hundredfold since Bio-Rad first invested in the company in 2003. In the early 2000s, Bio-Rad continued increasing its share of Sartorius, and has booked large (unrealized) gains on the investment since that time. With the Sartorius stake accounting for approximately half of the firm’s valuation, the investment has generated significant value for shareholders. We believe this is relevant in an evaluation of Bio-Rad’s stewardship, as current CEO Norman Schwartz has led the company since 2003, the year of the first investment in Sartorius, and oversaw the increase of the investment in subsequent years."  Morningstar
              0
              • underestimated stock
                0
                Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
                Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.